Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological ...

It will receive follow-on capital from existing backer Alphabet. The London-based company’s goal is an ambitious one – to “solve all disease,” according to the Isomorphic Labs site.

Isomorphic Labs is the secretive AI life science startup spun out of Google DeepMind with the goal of solving all disease ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

aiming to 'reimagine' the entire drug discovery process Isomorphic Labs, a subsidiary of Google parent Alphabet that uses artificial intelligence (AI) for drug discovery, announced on March 31 ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...